Irreversible corneal decompensation in patients treated with topical dorzolamide

A. Konowal, John Morrison, S. V L Brown, D. L. Cooke, L. J. Maguire, D. V. Verdier, Frederick (Fritz) Fraunfelder, R. F. Dennis, R. J. Epstein

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

PURPOSE: To describe irreversible corneal decompensation after topical dorzolamide hydrochloride (Trusopt; Merck and Co, Inc, West Point, Pennsylvania) therapy in nine patients who had histories consistent with corneal endothelial compromise. METHOD: Multicenter review of patients' charts. RESULTS: Nine eyes of nine patients developed overt corneal decompensation after starting topical dorzolamide, a condition that did not resolve with drug cessation. This occurred after 3 to 20 weeks (mean, 7.8) of therapy. All nine patients had undergone intraocular surgery. Eight patients had undergone cataract surgery; three were aphakic and three had posterior chamber intraocular lenses. Two patients had anterior chamber intraocular lenses and also had undergone trabeculectomies. Four patients had undergone penetrating keratoplasties, each case complicated by episodes of corneal allograft rejection that were successfully treated. Two patients had asymptomatic Fuchs endothelial dystrophy. Seven patients have since undergone successful penetrating keratoplasties. CONCLUSION: The reports suggest that dorzolamide can cause irreversible corneal edema in a subset of glaucoma patients with endothelial compromise. The findings suggest a rationale for research into the long-term effects of dorzolamide on the corneal endothelium.

Original languageEnglish (US)
Pages (from-to)403-406
Number of pages4
JournalAmerican Journal of Ophthalmology
Volume127
Issue number4
DOIs
StatePublished - Apr 1999

Fingerprint

dorzolamide
Penetrating Keratoplasty
Intraocular Lenses
Fuchs' Endothelial Dystrophy
Corneal Edema
Corneal Endothelium
Trabeculectomy

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Konowal, A., Morrison, J., Brown, S. V. L., Cooke, D. L., Maguire, L. J., Verdier, D. V., ... Epstein, R. J. (1999). Irreversible corneal decompensation in patients treated with topical dorzolamide. American Journal of Ophthalmology, 127(4), 403-406. https://doi.org/10.1016/S0002-9394(98)00438-3

Irreversible corneal decompensation in patients treated with topical dorzolamide. / Konowal, A.; Morrison, John; Brown, S. V L; Cooke, D. L.; Maguire, L. J.; Verdier, D. V.; Fraunfelder, Frederick (Fritz); Dennis, R. F.; Epstein, R. J.

In: American Journal of Ophthalmology, Vol. 127, No. 4, 04.1999, p. 403-406.

Research output: Contribution to journalArticle

Konowal, A, Morrison, J, Brown, SVL, Cooke, DL, Maguire, LJ, Verdier, DV, Fraunfelder, FF, Dennis, RF & Epstein, RJ 1999, 'Irreversible corneal decompensation in patients treated with topical dorzolamide', American Journal of Ophthalmology, vol. 127, no. 4, pp. 403-406. https://doi.org/10.1016/S0002-9394(98)00438-3
Konowal, A. ; Morrison, John ; Brown, S. V L ; Cooke, D. L. ; Maguire, L. J. ; Verdier, D. V. ; Fraunfelder, Frederick (Fritz) ; Dennis, R. F. ; Epstein, R. J. / Irreversible corneal decompensation in patients treated with topical dorzolamide. In: American Journal of Ophthalmology. 1999 ; Vol. 127, No. 4. pp. 403-406.
@article{f4e5a530d77646f8b15c46591418cf07,
title = "Irreversible corneal decompensation in patients treated with topical dorzolamide",
abstract = "PURPOSE: To describe irreversible corneal decompensation after topical dorzolamide hydrochloride (Trusopt; Merck and Co, Inc, West Point, Pennsylvania) therapy in nine patients who had histories consistent with corneal endothelial compromise. METHOD: Multicenter review of patients' charts. RESULTS: Nine eyes of nine patients developed overt corneal decompensation after starting topical dorzolamide, a condition that did not resolve with drug cessation. This occurred after 3 to 20 weeks (mean, 7.8) of therapy. All nine patients had undergone intraocular surgery. Eight patients had undergone cataract surgery; three were aphakic and three had posterior chamber intraocular lenses. Two patients had anterior chamber intraocular lenses and also had undergone trabeculectomies. Four patients had undergone penetrating keratoplasties, each case complicated by episodes of corneal allograft rejection that were successfully treated. Two patients had asymptomatic Fuchs endothelial dystrophy. Seven patients have since undergone successful penetrating keratoplasties. CONCLUSION: The reports suggest that dorzolamide can cause irreversible corneal edema in a subset of glaucoma patients with endothelial compromise. The findings suggest a rationale for research into the long-term effects of dorzolamide on the corneal endothelium.",
author = "A. Konowal and John Morrison and Brown, {S. V L} and Cooke, {D. L.} and Maguire, {L. J.} and Verdier, {D. V.} and Fraunfelder, {Frederick (Fritz)} and Dennis, {R. F.} and Epstein, {R. J.}",
year = "1999",
month = "4",
doi = "10.1016/S0002-9394(98)00438-3",
language = "English (US)",
volume = "127",
pages = "403--406",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Irreversible corneal decompensation in patients treated with topical dorzolamide

AU - Konowal, A.

AU - Morrison, John

AU - Brown, S. V L

AU - Cooke, D. L.

AU - Maguire, L. J.

AU - Verdier, D. V.

AU - Fraunfelder, Frederick (Fritz)

AU - Dennis, R. F.

AU - Epstein, R. J.

PY - 1999/4

Y1 - 1999/4

N2 - PURPOSE: To describe irreversible corneal decompensation after topical dorzolamide hydrochloride (Trusopt; Merck and Co, Inc, West Point, Pennsylvania) therapy in nine patients who had histories consistent with corneal endothelial compromise. METHOD: Multicenter review of patients' charts. RESULTS: Nine eyes of nine patients developed overt corneal decompensation after starting topical dorzolamide, a condition that did not resolve with drug cessation. This occurred after 3 to 20 weeks (mean, 7.8) of therapy. All nine patients had undergone intraocular surgery. Eight patients had undergone cataract surgery; three were aphakic and three had posterior chamber intraocular lenses. Two patients had anterior chamber intraocular lenses and also had undergone trabeculectomies. Four patients had undergone penetrating keratoplasties, each case complicated by episodes of corneal allograft rejection that were successfully treated. Two patients had asymptomatic Fuchs endothelial dystrophy. Seven patients have since undergone successful penetrating keratoplasties. CONCLUSION: The reports suggest that dorzolamide can cause irreversible corneal edema in a subset of glaucoma patients with endothelial compromise. The findings suggest a rationale for research into the long-term effects of dorzolamide on the corneal endothelium.

AB - PURPOSE: To describe irreversible corneal decompensation after topical dorzolamide hydrochloride (Trusopt; Merck and Co, Inc, West Point, Pennsylvania) therapy in nine patients who had histories consistent with corneal endothelial compromise. METHOD: Multicenter review of patients' charts. RESULTS: Nine eyes of nine patients developed overt corneal decompensation after starting topical dorzolamide, a condition that did not resolve with drug cessation. This occurred after 3 to 20 weeks (mean, 7.8) of therapy. All nine patients had undergone intraocular surgery. Eight patients had undergone cataract surgery; three were aphakic and three had posterior chamber intraocular lenses. Two patients had anterior chamber intraocular lenses and also had undergone trabeculectomies. Four patients had undergone penetrating keratoplasties, each case complicated by episodes of corneal allograft rejection that were successfully treated. Two patients had asymptomatic Fuchs endothelial dystrophy. Seven patients have since undergone successful penetrating keratoplasties. CONCLUSION: The reports suggest that dorzolamide can cause irreversible corneal edema in a subset of glaucoma patients with endothelial compromise. The findings suggest a rationale for research into the long-term effects of dorzolamide on the corneal endothelium.

UR - http://www.scopus.com/inward/record.url?scp=0033119461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033119461&partnerID=8YFLogxK

U2 - 10.1016/S0002-9394(98)00438-3

DO - 10.1016/S0002-9394(98)00438-3

M3 - Article

C2 - 10218692

AN - SCOPUS:0033119461

VL - 127

SP - 403

EP - 406

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 4

ER -